Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

Table 3 Adverse Events during the 12-Week Open-Label Treatment Phase

Adverse Events	Persistent PTH (n = 100)
All Events
≥ 1 Adverse Event	78
≥ 1 Treatment-Related Adverse Event	38
≥ 1 Serious Adverse Event	0
Any Adverse Event leading to Study Discontinuation	2
Adverse Events occurring in ≥ 2% of Patients^a
Injection-Site Reactions
Pain	7
Erythema	5
Hemorrhage	3
Acid Reflux	1
Constipation	30
Diarrhea	2
Dizziness	9
Dry Mouth	4
Fatigue	5
Hot Flashes	3
Influenza	2
Irregular Menstruation	3
Low Back Pain	2
Nausea	7
Palpitations	2
Upper Abdominal Pain	5
Worsened Headache	8

Data are reported as number of patients. If a patient had the same adverse event more than once, it was counted only once

ISSN: 1129-2377